Trade Mark Journal No.2026/034 21 August 2026
WO0000001931431 (5)
Office of origin: United States of America
Date of International Registration:5 June 2026
Date of designation in the UK:
5 June 2026

International priority date claimed: 3 June 2026
(United States of America)
(99862585)
- Class 5
- Pharmaceutical preparations for the treatment of immune system related diseases and disorders, complement-mediated diseases and disorders, and neurological diseases and disorders; pharmaceutical preparations for the treatment of Guillain-Barré syndrome.
Annexon, Inc.
Representative: Joshua S. Jarvis, Esq. Foley Hoag LLP, 155 Seaport Boulevard,, Seaport West, Boston MA 02210-2600, UNITED STATES OF AMERICA